Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524545 · ClinicalTrials.gov registry record · Phase 1
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
A Phase 1 study, sponsored by ALX Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05524545 is a Phase 1 study that has completed, run by ALX Oncology. The registered enrollment target is 36 participants.
The verdict
NCT05524545, a Phase 1 study, has completed, sponsored by ALX Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Interventions
- DRUG Enfortumab Vedotin
- DRUG Evorpacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2025-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05524545
The ClinicalTrials.gov registry entry for NCT05524545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enfortumab Vedotin is the first listed.
NCT05524545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05524545 about?
NCT05524545 is a clinical study titled "A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)". AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
What is the current status of trial NCT05524545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-11-02. Estimated completion is 2025-06-27.
What interventions are being tested in trial NCT05524545?
The interventions under investigation include: Enfortumab Vedotin (DRUG), Evorpacept (DRUG).
Who is sponsoring clinical trial NCT05524545?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.